Asher Biotherapeutics, also known as Asher Bio, is a biotechnology company developing immunotherapies intended for cancer, autoimmune disorders, and infectious diseases. Asher Biotherapeutics was founded in 2019 by Ivana Djuretic and Andy Yeungand and is headquartered in San Francisco, CA. The company is committed to creating new treatment paradigms by using its proprietary cis-targeting platform to engineer therapies that selectively engage immune cells.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/16/2024 | Series C | $55MM | $xx.xx | $428.78MM | Astrazeneca, Boxer Capital, Bristol Myers Squibb, Janus Henderson Investors, Ra Capital, Third Rock Ventures, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
47,313,447
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Astrazeneca, Boxer Capital, Bristol Myers Squibb, Janus Henderson Investors, Ra Capital, Third Rock Ventures, Wellington Management
|
||||||
09/01/2021 | Series B | $108MM | $xx.xx | $281.98MM | Alexandria Venture Investments, Boxer Capital, Invus, Janus Henderson Investors, Logos Capital, Marshall Wace, Mission Biocapital, Ra Capital Management, Third Rock Ventures, Wellington Management Company | |
Price per Share
$xx.xx
Shares Outstanding
53,771,459
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.7x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Boxer Capital, Invus, Janus Henderson Investors, Logos Capital, Marshall Wace, Mission Biocapital, Ra Capital Management, Third Rock Ventures, Wellington Management Company
|
||||||
03/23/2021 | Series A | $55MM | $xx.xx | $79.5MM | Boxer Capital, Invus, Mbc Biolabs, Third Rock Ventures, Y Combinator | |
Price per Share
$xx.xx
Shares Outstanding
55,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Boxer Capital, Invus, Mbc Biolabs, Third Rock Ventures, Y Combinator
|
||||||
08/19/2019 | Series Seed-1 | $150,003.00 | $xx.xx | $7.7MM | Y Combinator | |
Price per Share
$xx.xx
Shares Outstanding
1,050,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Y Combinator
|
||||||
08/19/2019 | Series Seed-2 | $290,000.00 | $xx.xx | $7.7MM | Y Combinator | |
Price per Share
$xx.xx
Shares Outstanding
362,500
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Y Combinator
|
||||||
08/19/2019 | Series Seed-3 | $3.21MM | $xx.xx | $7.7MM | Y Combinator | |
Price per Share
$xx.xx
Shares Outstanding
3,210,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Y Combinator
|